Pacira Pharmaceuticals Inc (PCRX) Shares Sold by State Street Corp

State Street Corp lowered its stake in shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) by 1.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,078,693 shares of the company’s stock after selling 19,491 shares during the period. State Street Corp owned 2.88% of Pacira Pharmaceuticals worth $34,834,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. BlackRock Fund Advisors boosted its position in Pacira Pharmaceuticals by 5.7% in the third quarter. BlackRock Fund Advisors now owns 1,682,381 shares of the company’s stock worth $57,571,000 after buying an additional 90,693 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in shares of Pacira Pharmaceuticals by 4.4% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 943,934 shares of the company’s stock worth $32,301,000 after buying an additional 39,713 shares during the last quarter. Schroder Investment Management Group raised its stake in shares of Pacira Pharmaceuticals by 38.5% in the third quarter. Schroder Investment Management Group now owns 663,456 shares of the company’s stock worth $22,703,000 after buying an additional 184,256 shares during the last quarter. Stephens Investment Management Group LLC raised its stake in shares of Pacira Pharmaceuticals by 6.8% in the third quarter. Stephens Investment Management Group LLC now owns 618,505 shares of the company’s stock worth $21,165,000 after buying an additional 39,295 shares during the last quarter. Finally, Rock Springs Capital Management LP raised its stake in shares of Pacira Pharmaceuticals by 6.7% in the third quarter. Rock Springs Capital Management LP now owns 504,000 shares of the company’s stock worth $17,247,000 after buying an additional 31,500 shares during the last quarter.

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) traded down 1.692% on Friday, reaching $45.025. The company’s stock had a trading volume of 300,939 shares. Pacira Pharmaceuticals Inc has a 52-week low of $29.95 and a 52-week high of $62.50. The company’s market cap is $1.69 billion. The stock has a 50-day moving average of $46.95 and a 200 day moving average of $38.97.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings data on Wednesday, March 1st. The company reported $0.09 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.01 by $0.08. The business earned $72.90 million during the quarter, compared to analysts’ expectations of $73.08 million. During the same quarter in the previous year, the firm earned $0.20 earnings per share. Pacira Pharmaceuticals’s revenue was up 5.2% on a year-over-year basis. On average, equities research analysts forecast that Pacira Pharmaceuticals Inc will post $0.28 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.chaffeybreeze.com/2017/04/21/state-street-corp-reduces-position-in-pacira-pharmaceuticals-inc-pcrx-updated-updated.html.

A number of brokerages have recently commented on PCRX. Wedbush reissued an “outperform” rating and set a $89.00 price target on shares of Pacira Pharmaceuticals in a research note on Wednesday. Royal Bank of Canada began coverage on Pacira Pharmaceuticals in a research note on Thursday, April 13th. They set an “outperform” rating and a $58.00 price target on the stock. Jefferies Group LLC set a $60.00 price target on Pacira Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, April 4th. Canaccord Genuity reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Pacira Pharmaceuticals in a research note on Wednesday, March 29th. Finally, Mizuho cut their price objective on Pacira Pharmaceuticals from $59.00 to $54.00 and set a “buy” rating on the stock in a research note on Thursday, March 23rd. Two analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $55.42.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

5 Day Chart for NASDAQ:PCRX

Receive News & Ratings for Pacira Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply